Matches in SemOpenAlex for { <https://semopenalex.org/work/W2612135927> ?p ?o ?g. }
- W2612135927 endingPage "5508" @default.
- W2612135927 startingPage "5503" @default.
- W2612135927 abstract "Cerebral cavernous malformations (CCMs) are common vascular anomalies that develop in the central nervous system and, more rarely, the retina. The lesions can cause headache, seizures, focal neurological deficits, and hemorrhagic stroke. Symptomatic lesions are treated according to their presentation; however, targeted pharmacological therapies that improve the outcome of CCM disease are currently lacking. We performed a high-throughput screen to identify Food and Drug Administration-approved drugs or other bioactive compounds that could effectively suppress hyperproliferation of mouse brain primary astrocytes deficient for CCM3. We demonstrate that fluvastatin, an inhibitor of 3-hydroxy-3-methyl-glutaryl (HMG)-CoA reductase and the N-bisphosphonate zoledronic acid monohydrate, an inhibitor of protein prenylation, act synergistically to reverse outcomes of CCM3 loss in cultured mouse primary astrocytes and in Drosophila glial cells in vivo. Further, the two drugs effectively attenuate neural and vascular deficits in chronic and acute mouse models of CCM3 loss in vivo, significantly reducing lesion burden and extending longevity. Sustained inhibition of the mevalonate pathway represents a potential pharmacological treatment option and suggests advantages of combination therapy for CCM disease." @default.
- W2612135927 created "2017-05-19" @default.
- W2612135927 creator A5005079725 @default.
- W2612135927 creator A5009479926 @default.
- W2612135927 creator A5013113053 @default.
- W2612135927 creator A5018571414 @default.
- W2612135927 creator A5026837431 @default.
- W2612135927 creator A5034176671 @default.
- W2612135927 creator A5056350826 @default.
- W2612135927 creator A5080417818 @default.
- W2612135927 date "2017-05-12" @default.
- W2612135927 modified "2023-10-18" @default.
- W2612135927 title "Combined HMG-COA reductase and prenylation inhibition in treatment of CCM" @default.
- W2612135927 cites W132683945 @default.
- W2612135927 cites W169014411 @default.
- W2612135927 cites W1896836582 @default.
- W2612135927 cites W1957113176 @default.
- W2612135927 cites W1972387348 @default.
- W2612135927 cites W1973096186 @default.
- W2612135927 cites W1985356361 @default.
- W2612135927 cites W2004220217 @default.
- W2612135927 cites W2012399826 @default.
- W2612135927 cites W2023388112 @default.
- W2612135927 cites W2027272443 @default.
- W2612135927 cites W2030839478 @default.
- W2612135927 cites W2045892052 @default.
- W2612135927 cites W2048445712 @default.
- W2612135927 cites W2058599028 @default.
- W2612135927 cites W2066448365 @default.
- W2612135927 cites W2067489256 @default.
- W2612135927 cites W2071822598 @default.
- W2612135927 cites W2073235331 @default.
- W2612135927 cites W2094098398 @default.
- W2612135927 cites W2105924650 @default.
- W2612135927 cites W2108920663 @default.
- W2612135927 cites W2115636228 @default.
- W2612135927 cites W2116227658 @default.
- W2612135927 cites W2124940469 @default.
- W2612135927 cites W2144798562 @default.
- W2612135927 cites W2146990673 @default.
- W2612135927 cites W2147327763 @default.
- W2612135927 cites W2154304147 @default.
- W2612135927 cites W2160457774 @default.
- W2612135927 cites W2169244169 @default.
- W2612135927 cites W2171538469 @default.
- W2612135927 cites W2171601824 @default.
- W2612135927 cites W2175209522 @default.
- W2612135927 cites W2176744910 @default.
- W2612135927 cites W2333129081 @default.
- W2612135927 cites W2358744153 @default.
- W2612135927 cites W2416369577 @default.
- W2612135927 cites W2555936050 @default.
- W2612135927 cites W808349522 @default.
- W2612135927 doi "https://doi.org/10.1073/pnas.1702942114" @default.
- W2612135927 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5448170" @default.
- W2612135927 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28500274" @default.
- W2612135927 hasPublicationYear "2017" @default.
- W2612135927 type Work @default.
- W2612135927 sameAs 2612135927 @default.
- W2612135927 citedByCount "24" @default.
- W2612135927 countsByYear W26121359272018 @default.
- W2612135927 countsByYear W26121359272019 @default.
- W2612135927 countsByYear W26121359272020 @default.
- W2612135927 countsByYear W26121359272021 @default.
- W2612135927 countsByYear W26121359272022 @default.
- W2612135927 countsByYear W26121359272023 @default.
- W2612135927 crossrefType "journal-article" @default.
- W2612135927 hasAuthorship W2612135927A5005079725 @default.
- W2612135927 hasAuthorship W2612135927A5009479926 @default.
- W2612135927 hasAuthorship W2612135927A5013113053 @default.
- W2612135927 hasAuthorship W2612135927A5018571414 @default.
- W2612135927 hasAuthorship W2612135927A5026837431 @default.
- W2612135927 hasAuthorship W2612135927A5034176671 @default.
- W2612135927 hasAuthorship W2612135927A5056350826 @default.
- W2612135927 hasAuthorship W2612135927A5080417818 @default.
- W2612135927 hasBestOaLocation W26121359271 @default.
- W2612135927 hasConcept C104950815 @default.
- W2612135927 hasConcept C126322002 @default.
- W2612135927 hasConcept C127413603 @default.
- W2612135927 hasConcept C134651460 @default.
- W2612135927 hasConcept C150903083 @default.
- W2612135927 hasConcept C181199279 @default.
- W2612135927 hasConcept C207001950 @default.
- W2612135927 hasConcept C2776329913 @default.
- W2612135927 hasConcept C2776839432 @default.
- W2612135927 hasConcept C2778163477 @default.
- W2612135927 hasConcept C2778417548 @default.
- W2612135927 hasConcept C2778827360 @default.
- W2612135927 hasConcept C2779519902 @default.
- W2612135927 hasConcept C2779982574 @default.
- W2612135927 hasConcept C2780645631 @default.
- W2612135927 hasConcept C502942594 @default.
- W2612135927 hasConcept C529278444 @default.
- W2612135927 hasConcept C55493867 @default.
- W2612135927 hasConcept C57790582 @default.
- W2612135927 hasConcept C71924100 @default.
- W2612135927 hasConcept C78519656 @default.
- W2612135927 hasConcept C86803240 @default.